期刊文献+

甲状腺相关眼病患者血清中白细胞介素-15和白细胞介素-21的含量及临床意义 被引量:3

Contents and clinical significances of interleukin-15 and interleukin-21 in serum of thyroid-associated ophthalmopathy patients
下载PDF
导出
摘要 目的探讨甲状腺相关眼病(thyroid-associated ophthalmopathy,TAO)患者血清中白细胞介素-15(interleukin-15,IL-15)和IL-21的含量变化及其临床意义。方法收集2011年6月至2012年4月于我院诊断为TAO患者的资料及血清样本76例,参照TAO临床活动度评分(clinicalactivityscore,CAS)标准将患者分为非典型活动期(CAS<4分)组(33例)和活动期(CAS≥4分)组(43例),根据TAO眼部改变并结合CAS将其又分为非浸润组(30例)和浸润组(46例)。另收集同期正常体检血清标本35例作为正常对照组。采用酶联免疫吸附实验(ELISA)检测各组血清中IL-15和IL-21的含量。结果 TAO活动期组患者血清中IL-15和IL-21的含量分别为(389.42±278.32)pg·mL-1、(248.54±157.32)pg·mL-1,TAO非活动期组分别为(45.06±8.54)pg·mL-1、(12.62±6.47)pg·mL-1,正常对照组分别为(26.67±5.86)pg·mL-1、(7.58±5.49)pg·mL-1。TAO活动期组患者血清中IL-15和IL-21的含量均明显高于TAO非活动期组和正常对照组,差异均有显著统计学意义(均为P<0.01);TAO非活动期组患者血清中IL-15和IL-21的含量高于正常对照组,差异均有统计学意义(均为P<0.05)。浸润性TAO组患者血清中IL-15和IL-21的含量分别为(358.12±248.51)pg·mL-1、(218.45±119.42)pg·mL-1,均明显高于非浸润性TAD组的(29.06±6.79)pg·mL-1、(7.79±5.58)pg·mL-1和正常对照组,差异均有显著统计学意义(均为P<0.01);非浸润性TAO组患者血清中IL-15和IL-21含量稍高于正常对照组,但差异均无统计学意义(均为P>0.05)。结论血清中IL-15和IL-21的含量检测可用于评估TAO的炎症活动性和浸润情况。 Objective To investigate the contents and clinical significances of in terleukin-15 ( IL-15 ) and IL-21 in serum of thyroid-associated ophthalmopathy (TAO) pa tients. Methods A total of 76 TAO patients with their data and blood samples were collected in our hospital from June 2011 to April 2012 ,then they were divided into TAO inactive period group ( CAS 〈 4 points, 33 cases) and TAO active period group ( CAS 〉 4 points,43 cases) by TAO clinical activity score standard, and were divided into non in vasive TAO group (30 cases) and invasive TAO group (46 cases) by eye complications combined with CAS. Another 35 normal cases with their blood samples were collected as normal group. The content of IL-15 and IL-21 in serum of patients were detected by ELISA. Results The content of IL-15 and IL-21 in serum of TAO active period group were ( 389.42 ± 278.32 ) pg · mL - 1 and ( 248.54 ± 157.32 ) pg · mL 1, TAO inactive period group were(45.06 ± 8.54)pg · mL-1 and( 12.62 ± 6.47 ) pg · mL-1 , and normal control group were (26.67 ± 5.86) pg · mL- 1 and ( 7.58 ± 5.49) pg · mL- 1. As to the content of IL-15 and IL-21 in serum, TAO active period group were both significantly obviously higher than those of TAO inactive period group and normal control group( all P 〈 0.01 ), and TAO inactive period group were both significantly higher than those of normal con-trol group(both P 〈 0.05 ) ;Invasive TAO group were both significantly obviously higher than those of non invasive TAO group and normal control group( all P 〈 0.01 ) ; Non invasive TAO group were both significantly a little higher than those of normal control group ( both P 〈 0.05 ). Conclusion The content detection of IL-15 and IL-21 in serum of TAO patients can be used to evaluate the situation of inflammation activities and infiltration.
出处 《眼科新进展》 CAS 北大核心 2013年第6期565-567,共3页 Recent Advances in Ophthalmology
关键词 甲状腺相关眼病 IL-15 IL-21 thyroid-associated ophthalmopathy interleukin-15 interleukin-21
  • 相关文献

参考文献12

二级参考文献187

  • 1王莉菲,吴中耀,杨华胜,颜建华,毛羽翔,陈智聪.甲状腺相关眼病患者眼眶前脂肪细胞的培养及分化[J].中山大学学报(医学科学版),2005,26(3):351-353. 被引量:9
  • 2许晓群,张建(审校者).白细胞介素21免疫学效应研究进展[J].国际免疫学杂志,2006,29(1):34-37. 被引量:3
  • 3肖春香,殷小成,尹珊辉,匡艳华,王金兰.哮喘患儿血清IL-18、IL-4和INF-γ水平测定的临床意义的研究[J].实用诊断与治疗杂志,2006,20(4):240-241. 被引量:13
  • 4中华医学会耳鼻咽喉科学分会.变应性鼻炎诊断标准及疗效评定标准[J].中华耳鼻咽喉科杂志,1998,33(3):134-134.
  • 5Parrish-Novak J, Dillon SR, Nelson A, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature, 2000, 408 (6808) :57-63.
  • 6Habib T, Senadheera S, Weinberg K, et al. The common gamma chain (gamma c) is a required signaling component of the IL-21 receptor and supports IL-21-induced cell proliferation via JAK3. Biochemistry, 2002, 41 (27) :8725-8731.
  • 7Brandt K, Bulfone-Paus S, Foster DC, et al. Interleukin-21 inhibits dendritic cell activation and maturation. Blood, 2003, 102 (12) :4090-4098.
  • 8Gowda A, Roda J, Hussain SR, et al. IL-21 mediates apoptosis through up-regulation of the BH3 family member BIM and enhances both direct and antibody-dependent cellular cytotoxicity in primary chronic lymphocytic leukemia cells in vitro. Blood, 2008, 111(9) :4723-4730.
  • 9Scheeren FA, Diehl SA, Smit LA, IL-21 is expressed in Hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for Hodgkin lymphomagenesis. Blood, 2008, 111 (9) : 4706-15.
  • 10Coquet JM, Kypafissoudis K, Pellicci DG, el al, IL-21 is produced by NKT cells and modulales NKT cell activation and cytokine production. J Immunol, 2007,178 (5) :2827-2834.

共引文献71

同被引文献47

  • 1叶小珍,王坚,胡兰萍,顾萍,李洁,邵加庆,王燕燕.碱性成纤维细胞生长因子-2在Graves眼病发病机制中的作用[J].中国全科医学,2009,12(16):1530-1531. 被引量:1
  • 2顾龙君.儿童急性淋巴细胞白血病诊疗建议(第三次修订草案)[J].中华儿科杂志,2006,44(5):392-395. 被引量:476
  • 3Onciu M. Acute lymphoblastie leukemia[J].Hematology/Oncology Clinics of North America,2009,(04):655-674.
  • 4Oleinika K,Nibbs BJ,Graham GJ. Suppression,subversion and escape:the role of regulatory T cells in cancer progression[J].Clinical & Experimental Immunology,2013,(01):36-45.
  • 5Facciabene A,Motz GT,Coukos G. T-regulaory cells:key players in tumor immune escape and angiogenesis[J].CANCER RESEARCH,2012,(09):2162-2171.
  • 6Rudensky A Y. Regulatory T cells and Foxp3[J].Immunological Reviews,2011,(01):260-268.
  • 7Beyer M,Classen S,Endl E. Comparative approach to define increased regulatory T cells in different cancer subtypes by combined assessment of CD127 and FOXP3[J].Clinical and Developmental Immunology,2011.734036.
  • 8Shenghui Z,Yixiang H,Jianbo W. Elevated frequencies of CD4 (+) CD25(+) CD127lo regulatory T cells is associated to poor prognosis in patients with acute myeloid leukemia[J].International Journal of Cancer,2011,(06):1373-1381.
  • 9Weiss L,Melchardt T,Egle A. Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia[J].CANCER,2011,(10):2163-2169.
  • 10Yamamoto T,Yanagimoto H,Satoi S. Circulating CD4+ CD25+ regulatory T cells in patients with pancreatic cancer[J].PANCREAS,2012,(03):409-415.

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部